Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease

…, J Donadieu, F Cohen-Aubart… - Blood, The Journal …, 2018 - ashpublications.org
Rosai-Dorfman-Destombes disease (RDD) is a rare non–Langerhans cell histiocytosis
characterized by accumulation of activated histiocytes within affected tissues. RDD, which now …

Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era

…, ML Heaney, M Collin, F Cohen-Aubart… - Blood, The Journal …, 2020 - ashpublications.org
Erdheim-Chester disease (ECD) is a rare histiocytosis that was recently recognized as a
neoplastic disorder owing to the discovery of recurrent activating MAPK (RAS-RAF-MEK-ERK) …

Acute pulmonary embolism: a review

Y Freund, F Cohen-Aubart, B Bloom - Jama, 2022 - jamanetwork.com
Importance Pulmonary embolism (PE) is characterized by occlusion of blood flow in a pulmonary
artery, typically due to a thrombus that travels from a vein in a lower limb. The incidence …

High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses

…, B Hervier, F Cohen-Aubart… - Blood, The Journal …, 2012 - ashpublications.org
Histiocytoses are rare disorders of unknown origin with highly heterogeneous prognosis.
BRAF mutations have been observed in Langerhans cell histiocytosis (LCH). We investigated …

Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E …

J Haroche, F Cohen-Aubart, JF Emile… - Blood, The Journal …, 2013 - ashpublications.org
Histiocytoses are rare disorders of unknown origin with highly heterogeneous prognosis.
BRAF V600E gain-of-function mutations have been observed in 57% of cases of Langerhans …

Diverse and targetable kinase alterations drive histiocytic neoplasms

…, SA Parikh, Z Wang, J Choi, E Kim, F Cohen-Aubart… - Cancer discovery, 2016 - AACR
Histiocytic neoplasms are clonal, hematopoietic disorders characterized by an accumulation
of abnormal, monocyte-derived dendritic cells or macrophages in Langerhans cell …

Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with …

…, J Rohmer, M Roumier, F Cohen-Aubart… - Annals of the …, 2020 - ard.bmj.com
The current outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
disease 2019 (COVID-19) represents a source of concern for the management of patients with …

[HTML][HTML] BRAF mutation correlates with high-risk Langerhans cell histiocytosis and increased resistance to first-line therapy

…, JL Stephan, F Cohen-Aubart… - Journal of clinical …, 2016 - ncbi.nlm.nih.gov
… Sébastien Héritier, corresponding author Jean-François Emile, Mohamed-Aziz Barkaoui,
Caroline Thomas, Sylvie Fraitag, Sabah Boudjemaa, Florence Renaud, Anne Moreau …

[PDF][PDF] Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF (V600E)-mutated Erdheim-Chester disease

J Haroche, F Cohen-Aubart, JF Emile, P Maksud… - J Clin Oncol, 2015 - academia.edu
Purpose Histiocytoses are rare disorders with heterogeneous prognosis. BRAFV600E mutations
have been observed in half of patients with Langerhans cell histiocytosis (LCH) and in …

Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease

…, Z Hélias-Rodzewicz, F Cohen-Aubart… - Blood, The Journal …, 2014 - ashpublications.org
Erdheim-Chester disease (ECD) is a rare histiocytic disorder that is challenging to diagnose
and treat. We performed molecular analysis of BRAF in the largest cohort of ECD patients …